Drugmakers that dominate the world's insulin market must scale up access efforts globally accesstomedicinefoundation.org/news/drugmaker…

STAT+: ‘Patchy efforts’ by major insulin makers mean access lags in many poor countries trib.al/dILKnD7

Scale Up Access to Insulin, Report Says Though the number of people with diabetes worldwide is expected to reach 643 mn by 2030, & 700 mn by 2045 – rising mostly in low & middle income countries (LMICs), access to #insulin remains limited 🔗bit.ly/3rE5Ryi CC Access to Medicine Foundation

Read how Dr.Buguzi writes about our new report on #AccessToInsulin in SciDev.Net 👇 #Insulin4All #diabetes

Nearly a century after insulin was discovered, millions of diabetes patients still have poor, or even no access, to the vital treatment trib.al/eabxSNu

Great to see our latest research report on #access to #insulin covered by SciDev.Net Access to Medicine Foundation

Truly saddened to read this piece of news... National regulatory agencies need to ensure that medicines are safe and effective bbc.com/news/world-afr…

World #MentalHealthDay is a stark reminder of the millions of people across the world (but especially in #lmics) who lack access to appropriate treatments. It is an urgent public health challenge that requires attention from the #globalhealth community, inc. the #pharma industry

Our Claudia Martínez V., Research Programme Manager, is joined by Gina Agiostratidou, Programme Director for the Helmsley Charitable Trust's Type 1 #Diabetes Programme, for a fireside chat to discuss the findings of our report that looks at #AccessToInsulin 👉 youtu.be/7A1jT8vB-dQ #Insulin4All

Our #T1D Program Director, Gina Agiostratidou, recently spoke with Access to Medicine Foundation Research Manager Claudia Martínez V. on their latest report “What are pharma companies doing to expand access to insulin – and how can efforts be scaled up?” Watch the full conversation here: bit.ly/3fSxhhb

Efforts by pharma to tackle global insulin inequity are “fragmented” and “falling short,” with many people with diabetes without access to the drug. “Fewer than 30% of LMICs currently have access to all insulins deemed essential," says Claudia Martínez V. bmj.com/content/379/bm…

Despite the devastating consequences of diabetes, there is a persistent gap in the world’s #AccessToInsulin, writes Dong Lyu for Bloomberg, in a news feature that looks at our latest report on #AccessToInsulin. Read it here 👇 bloomberg.com/news/newslette… #Insulin4All #diabetes

An important discussion on the need for #access to antibiotics and antifungals hosted by my amazing colleagues at Access to Medicine Foundation @FatemaRafiqi

Resharing this study by Olivier Wouters and colleagues published in @JAMA this last Sept 👉 No correlation was found between (high) prices charged by #pharma companies and the R&D costs that went into developing such drugs. jamanetwork.com/journals/jaman…

LAUNCHING TOMORROW: the first-ever framework for evaluating the actions of generic & biosimilar medicine manufacturers on #access2meds in #LMICs. 🎥 Claudia Martínez V. speaks about the framework & how it can be used as a tool to drive change 👉 youtu.be/BoQHqQP4pKg #StayTuned

📽️ Watch Claudia Martínez V. in conversation with Prof. Fatima Suleman, Prashant Yadav (@prof-yadav.bsky.social) & Nazeem Mohamed of Aga Khan Foundation about the opportunities for generic & biosimilar medicine manufacturers to further contribute to expanding equitable #access2meds in #LMICs 👇 youtu.be/8R543biZT1A

Listen up! 🎧 Our Research Programme Manager, Claudia Martínez V., spoke about how we stimulate the #healthcare industry to do more for people in #LMICs on the latest episode of the EMJ GOLD #Podcast, with Jade Williams. Check it out 👉 emg-gold.com/post/driving-a… @GOLD_pharma

Great to be quoted by The Guardian about the need for greater access to #insulin in #LMICs. Last year, here at the Access to Medicine Foundation we published a report looking at what the largest companies were doing to expand access to treatment, with some striking findings. bit.ly/3yXD7nR